Drug Profile
VS 01
Alternative Names: VS-01; VS-01-HACLatest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Genfit; Versantis
- Class Drug withdrawal therapies; Tricarboxylic acids
- Mechanism of Action Ammonia scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Hepatic encephalopathy; Liver failure
- Preclinical Hyperammonaemia; Inborn urea cycle disorders; Substance-related disorders
Most Recent Events
- 20 Sep 2023 VS 01 is still in preclinical trials for Inborn urea cycle disorders in Switzerland (Intraperitoneal, Liposomal)
- 02 Jul 2023 Phase-I/II clinical trials in Liver failure in France, Belgium, USA (Intraperitoneal) (NCT05900050)
- 13 Apr 2023 Versantis plans a phase II trial in Liver failure in the EU in the second quarter of 2023